To conduct a systematic review evaluating subjective patient reported outcomes (PROs), reoperations, and graft failure after concomitant osteochondral allograft (OCA) transplantation and meniscal allograft transplantation (MAT). A literature search was performed by querying MEDLINE, Embase, and PubMed according to the 2020 PRISMA statement. Inclusion criteria were limited to peer-reviewed English level I-IV studies with at least 10 patients reporting clinical outcomes and complications following OCA transplantation with concomitant MAT for osteochondral defects and meniscal deficiency with a minimum of 2-years follow up. For a majority of the included studies, failure was defined as conversion to arthroplasty, revision OCA, or graft failure on postoperative imaging. Six studies with a total of 188 patients met inclusion/exclusion criteria. The mean patient age was 32.4 years (Range 15 to 66 years). Improvement in the following outcome scores was observed across all included studies from pre- to postoperative status: Lysholm Knee Score (+21 to +26.69), International Knee Documentation Committee (IKDC) Subjective Knee Form (+19 to +26.55), Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Score (+17.91 to +26), KOOS Symptom Score (+9 to +18.16), KOOS Activities of Daily Living (ADL) Score (+11.91 to +23.4), KOOS Sport Score (+19 to +26.04), KOOS Quality of Life Score (+22 to +35.01), 12-Item Short Form Survey (SF-12) Physical Score (+5 to +12.26), and SF-12 Mental Score (+1.8 to +4) (P < 0.05 for all). Reoperation rate was found to be between 6.7% and 54%. Failure rate was found to be between 13% and 22.9%. Although patient satisfaction data was only available in 2 studies, 82% - 90% of patients would choose to undergo OCA transplantation with MAT again. OCA transplantation with concomitant MAT for the treatment of focal chondral defects in the presence of meniscus deficiency results in improved patient-reported outcome measures with high patient satisfaction rates. Reoperation rates and failure rates at a mean follow up time of 4.7 years (Range 1.7 to 17.1 years) are 37.3% and 17.1%, respectively, which are expected and consistent with the existing literature in isolated procedures. Level IV; Systematic Review of Level III-IV Studies.
Read full abstract